Join Tenax Therapeutics for LEVEL Setting, a panel of globally-recognized thought leaders in the field of heart failure, exploring the potential of TNX-103 (oral levosimendan) to treat patients with pulmonary hypertension from heart failure with preserved ejection fraction (PH-HFpEF). The event will be moderated by Stuart Rich, MD, Tenax Therapeutics’ Chief Medical Officer.

Expert panelists will review emerging science, clinical experience with TNX-103, and the evolving heart failure landscape:

• Understanding the setting of PH-HFpEF – Sanjiv Shah, MD (Northwestern University) 
• Mechanism of Action of Levosimendan – Daniel Burkhoff, MD, PhD (CRF/Columbia University)
• Review of data from the Phase 2 HELP Study – Barry Borlaug, MD (Mayo Clinic)
• Current treatment landscape in PH-HFpEF – Javed Butler, MD, MPH, MBA (Baylor Scott & White)

Following the discussion, members of Tenax Therapeutics senior management will provide a brief update on the ongoing Phase 3 LEVEL Study, followed by a Q&A session with the faculty.